Pharmaceuticals News and Research

RSS

Irvine Scientific announces launch of BalanCD MDCK cell culture medium

Irvine Scientific is pleased to announce the launch of its BalanCD MDCK cell culture medium, a next generation cell culture product responding to today's requirements for media used in cell-based vaccine manufacturing. This new flagship product expands Irvine Scientific's current BalanCD product portfolio of animal component-free and chemically-defined media with the addition of a new purpose-built product.

15 Apr 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.

15 Apr 2014

Prestige Brands Holdings signs agreement for acquisition of Hydralyte

Prestige Brands Holdings, Inc. today announced the signing of a purchase agreement for the acquisition of Hydralyte in Australia and New Zealand from The Hydration Pharmaceuticals Trust of Victoria, Australia. The acquisition is expected to close, subject to customary closing conditions, during the first quarter of fiscal 2015, which began on April 1, 2014.

15 Apr 2014

Study shows 25 percent of Colorado foster kids on psychotropic drugs

The rate is 12 times greater than for other children on government insurance, a new study in Colorado finds.

15 Apr 2014

Domain Therapeutics receives grant to support development of mGluR3 PAM for Parkinson’s disease

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces the receipt of a second grant of 230 000 dollars (USD) from The Michael J. Fox Foundation for Parkinson’s Research to support its metabotropic glutamate receptor type III (mGluR3) positive allosteric modulators (PAM) program.

15 Apr 2014

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

Twelve weeks of an investigational oral therapy cured hepatitis C infection in more than 90 percent of patients with liver cirrhosis and was well tolerated by these patients, according to an international study that included researchers from UT Medicine San Antonio and the Texas Liver Institute.

15 Apr 2014

McGill University Health Centre launches new program to improve patient safety and quality care

A new program aimed at improving patient safety and quality care has been launched at McGill University Health Centre hospitals. The program, which is being conducted in collaboration with Vendorlink.ca, is the first of its kind in a large academic Quebec hospital.

11 Apr 2014

Federal district court enforces settlement between Mylan and Endo Pharmaceuticals on generic FROVA

Mylan Inc. today confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for Frovatriptan Succinate Tablets, 2.5 mg.

11 Apr 2014

Impax resubmits NDA for RYTARY providing updated safety and stability information

Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced today the resubmission of Impax's New Drug Application (NDA) for RYTARY (IPX066) to the U.S. Food and Drug Administration (FDA).

11 Apr 2014

ICB International develops tracer for imaging alpha-synuclein in Parkinson's disease

On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like mice at the Keystone Symposium for Parkinson disease (PD) in Keystone,Colorado.

11 Apr 2014

Researchers show development of new cell models that track, report clock gene function

The consequences of modern life -- shift work, cell phone addiction, and travel across time zones -- all disturb internal clocks. These are found in the brain where they regulate sleep and throughout the body where they regulate physiology and metabolism.

11 Apr 2014

EU-funded project aims to find solution to combat hepatitis C epidemic in Egypt

New ways to differentiate between chronic and self-clearing infections may help towards effective patient management and reduce drug costs. But there are major challenges in implementation.

11 Apr 2014

Analysis of Medicare pay shows variations in drugs used and earnings by specialists

The Washington Post examines how drugs administered by doctors is different in various regions of the country. Other outlets look at other issues, including how eye doctors are among the highest paid specialty.

11 Apr 2014

Researchers untangle genetic and environmental factors related to drug reactions

Why do people respond differently to the same drug? For the first time, researchers have untangled genetic and environmental factors related to drug reactions, bringing us a step closer to predicting how a drug will affect us.

11 Apr 2014

Canaleaf Systems signs definitive agreement to purchase 50% of IHMML

Medican Enterprises Inc. a bio-pharmaceutical company in the emerging global medical marijuana industry is pleased to announce its wholly owned subsidiary Canaleaf Systems Inc. has signed a definitive purchase agreement to acquire 50 percent of International Herbs Medical Marijuana Ltd.

10 Apr 2014

Assembly Pharmaceuticals, BioCrossroads develop novel drugs that have potential to treat chronic HBV infection

Assembly Pharmaceuticals and BioCrossroads today announced that the BioCrossroads Indiana Seed Fund II has made an investment in Assembly Pharmaceuticals. Assembly is developing novel drugs for the treatment and potential cure of chronic hepatitis B virus (HBV) infection.

10 Apr 2014

First Edition: April 10, 2014

Today's headlines include a range of stories taking additional looks at the Medicare physician payment data released yesterday by the Centers for Medicare & Medicaid Services.

10 Apr 2014

Study: CD206-targeting Manocept platform may provide potential avenues to enhance diagnosis in Kaposi Sarcoma

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that collaborators from the University of California, San Francisco (UCSF) presented results at the 2014 American Association for Cancer Research (AACR) conference, April 5-9, 2014 in San Diego, CA, highlighting the potential utility of imaging agents derived from Navidea's Manocept™ platform in identifying affected tissues and lymph nodes in patients with Kaposi Sarcoma (KS).

10 Apr 2014

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's BL-8040 as a treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study.

10 Apr 2014

Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

With just one month until 2014 Biotech China, experts, entrepreneurs and decision-makers from the international biotechnology industry will gather at the heart of the Chinese biotechnology industry on May 14-16th, 09:00 AM-06:00 PM in Nanjing China.

10 Apr 2014

Pharmaceuticals News and Research

Irvine Scientific announces launch of BalanCD MDCK cell culture medium

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Prestige Brands Holdings signs agreement for acquisition of Hydralyte

Study shows 25 percent of Colorado foster kids on psychotropic drugs

Domain Therapeutics receives grant to support development of mGluR3 PAM for Parkinson’s disease

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

McGill University Health Centre launches new program to improve patient safety and quality care

Federal district court enforces settlement between Mylan and Endo Pharmaceuticals on generic FROVA

Impax resubmits NDA for RYTARY providing updated safety and stability information

ICB International develops tracer for imaging alpha-synuclein in Parkinson's disease

Researchers show development of new cell models that track, report clock gene function

EU-funded project aims to find solution to combat hepatitis C epidemic in Egypt

Analysis of Medicare pay shows variations in drugs used and earnings by specialists

Researchers untangle genetic and environmental factors related to drug reactions

Canaleaf Systems signs definitive agreement to purchase 50% of IHMML

Assembly Pharmaceuticals, BioCrossroads develop novel drugs that have potential to treat chronic HBV infection

First Edition: April 10, 2014

Study: CD206-targeting Manocept platform may provide potential avenues to enhance diagnosis in Kaposi Sarcoma

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence